Key Stats for Arrowhead Pharma Stock
- Price change for Arrowhead Pharma stock: 2%
- $ARWR Share Price as of May. 4: $76
- 52-Week High: $77
- $ARWR Stock Price Target: $85
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Arrowhead Pharmaceuticals (ARWR) stock got a lift on Friday after JPMorgan initiated coverage with an Overweight rating and an $88 price target. That implies about 20% upside from where shares were trading.
Analyst Brian Cheng highlighted the company’s diversified RNAi pipeline as the key reason for the bullish call.
RNAi, or RNA interference, is a technology that can silence specific genes driving disease. Arrowhead has built one of the most diversified platforms in this space, with programs targeting cardiovascular disease, obesity, neurodegeneration, and rare diseases.
The near-term story centers on REDEMPLO, Arrowhead’s newly approved drug for Familial Chylomicronemia Syndrome, or FCS — a rare condition where dangerously high triglyceride levels can cause life-threatening pancreatitis.
- The FDA approved REDEMPLO in November 2025, making it Arrowhead’s first commercial product.
- The launch is going well. Over 100 prescriptions have already been written till February 2026, with geographically balanced uptake across the U.S. Most patients are new to this class of drug, which is a good sign for long-term growth.
But JPMorgan’s bigger interest is what comes next. Arrowhead is running three Phase III studies of plozasiran — the same drug as REDEMPLO — in a much larger population of patients with severe hypertriglyceridemia, or SHTG.
Results from the SHASTA-3 and SHASTA-4 studies are expected in Q3 2026. If positive, Arrowhead plans to file for a label expansion before year-end. Management believes the SHTG opportunity could be worth $3-$4 billion commercially.
Beyond that, Arrowhead Pharmaceuticals stock also carries exposure to early-stage obesity programs.
The company recently reported that its ARO-INHBE candidate, when combined with the popular weight-loss drug tirzepatide, achieved roughly twice the weight loss versus tirzepatide alone in obese diabetic patients. That result caught attention across the biotech space.
A CNS program targeting Alzheimer’s disease — ARO-MAPT — also dosed its first patients recently, with initial data expected later this year.
The company ended the quarter with around $917 million in cash before factoring in over $1.3 billion in additional proceeds raised since then through milestone payments, a Novartis licensing deal, and capital markets transactions.
See analysts’ growth forecasts and price targets for Arrowhead Pharma stock (It’s free) >>>
What the Market Is Telling Us About Arrowhead Pharma Stock
Arrowhead Pharmaceuticals stock has a lot of near-term catalysts lined up.
The SHASTA data readout in Q3 is the biggest one to watch. A positive result would validate the drug in a much larger market and likely drive a meaningful re-rating of the stock.
JPMorgan’s initiation adds credibility to the bull case.
With a strong balance sheet, a commercial product already on the market, and multiple data readouts ahead, Arrowhead Pharmaceuticals stock looks like one of the more interesting biotech setups of 2026.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Arrowhead Pharma Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
